Mode
Text Size
Log in / Sign up

Clinical Trial Search

Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.

Phase
Intervention
Population
Results posted

30 closest matches · ranked by relevance

Phase 2 N=75 Peanut Epicutaneous Phase II Immunotherapy Clinical Trial

Peanut Hypersensitivity · Food Hypersensitivity · Hypersensitivity
Primary: Percentage of Subjects With a Successful Treatment Response — 12.0; 45.8; 48.0 percentage of participants — p=0.005
National Institute of Allergy and Infectious… Results Aug 2016 3.2% serious AE View details

Phase 2 N=60 Multi Immunotherapy to Test Tolerance and Xolair

Food Allergy
Primary: The Number of Participants Able to Tolerate an Oral Food Challenge to 2,000 mg at Least of 2 Allergens at Week 36 (i.e. the End of the Randomized Withdrawal/Tolerance…
Kari Christine Nadeau Results Dec 2017 0.8% serious AE View details

Phase 2 N=55 Oral Immunotherapy for Childhood Egg Allergy

Hypersensitivity · Immediate Hypersensitivity · Food Hypersensitivity
Primary: Percent of Participants Who Successfully Consumed 10,000 mg of Egg White Solid Followed by Open Feeding of Egg — 27.5; 0 percentage of participants — p=0.025
National Institute of Allergy and Infectious… Results May 2012 4.4% serious AE View details

Phase 2 N=6 Inhibition of Anaphylaxis by Ibrutinib

Food Allergy · Anaphylaxis Food
Primary: Number of Doses of Ibrutinib for Maximal Suppression of Skin Prick Test Size to Foods — 2 doses — p=<0.0001
Ann & Robert H Lurie Children's Hospital of… Results Jan 2025 0.0% serious AE View details

Phase 2 N=46 Oral Immunotherapy for Wheat Allergy

Wheat Allergy
Primary: The Percentage of Desensitized Participants as Measured by the Ability to Consume at Least 4443 mg of Wheat Protein During a 7443 mg Wheat Protein Oral Food Challenge…
Hugh A Sampson, MD Results Mar 2017 5.6% serious AE View details

Phase 2 N=10 Oral Immunotherapy for Peanut Allergy (PMIT)

Food Hypersensitivity
Primary: The Amount of Peanut Protein Ingested Before An Allergic Reaction is Observed During the Double-blind, Placebo Controlled Food Challenge (DBPCFC) After Completing…
University of North Carolina, Chapel Hill Results May 2017 0.0% serious AE View details

Phase 2 N=14 Omalizumab in the Treatment of Peanut Allergy

Food Allergy · Peanut Allergy
Primary: Number of Participants Who Experienced a Decrease in Pn-BHR Area Under the Curve (AUC) of > 80% Compared With Baseline Values Before Week 8 — 5; 9 Participants
Johns Hopkins University Results Jul 2017 0.0% serious AE View details

Phase 2 N=16 Oral Immunotherapy (OIT) for Peanut Allergy

Peanut Hypersensitivity
Primary: Percentage of Subjects Achieving Tolerance as Defined by a Negative DBPCFC 4 Weeks After Discontinuation of Peanut OIT Therapy. — 89 percentage of participants
University of North Carolina, Chapel Hill Results May 2017 0.0% serious AE View details